Pulse Check: The Cardiovascular Conversations

In episode two, the conversation turns to clinical development and the power of imaging biomarkers. Dr. Cheerag Shirodaria (Fortrea) and Chris Farina (Abcentra) delve into how innovations in technology and imaging, such as coronary CT angiography (CCTA) and the Fat Attenuation Index (FAI) are transforming risk stratification—reclassifying patients and identifying inflammation even in those with “normal” arteries. The episode also highlights the challenges of trial design in novel populations and the critical role of sponsor-CRO-vendor collaborations, including Fortrea’s CRO support. For pharma teams focused on precision medicine and inflammation-targeted therapies, this episode offers valuable insights into the future of cardiovascular care.

Despite advances in lipid-lowering and antithrombotic therapies, residual cardiovascular risk remains a major challenge. In this episode, Dr. Cheerag Shirodaria, Fortrea's cardiovascular lead, and Chris Farina, CEO of Abcentra, explore the emerging science behind coronary inflammation as a key driver of atherosclerotic disease. They discuss why inflammation, particularly in vulnerable coronary plaques, is gaining traction as a therapeutic target, and talk about Abcentra’s first-in-class monoclonal antibody - designed to selectively quell inflammation in diseased arterial tissue. With insights from landmark trials, and a look at how these new options differs from systemic anti-inflammatory agents, this episode offers a compelling case for a paradigm shift in cardiovascular drug development. If you're working in CV research, this is a must-listen.